This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RYH)?
by Zacks Equity Research
Sector ETF report for RYH
Is Invesco S&P 500 Equal Weight Health Care ETF (RYH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RYH
Illumina (ILMN) Progresses in Pathogen Genomic Technologies
by Zacks Equity Research
Illumina's (ILMN) genomic surveillance solutions enable better pathogen preparedness and response.
Illumina (ILMN) Q1 Earnings Beat Estimates, Margins Contract
by Zacks Equity Research
Illumina's (ILMN) Q1 revenues decline year over year, reflecting the impact of Covid-19 monitoring headwinds and the transition of its high-throughput customers to NovaSeq X.
Illumina (ILMN) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Illumina (ILMN) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Illumina (ILMN) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Illumina (ILMN) delivered earnings and revenue surprises of 300% and 2.42%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
EXEL or ILMN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EXEL vs. ILMN: Which Stock Is the Better Value Option?
Tarsus Pharmaceuticals, Inc. (TARS) Soars 8.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Tarsus Pharmaceuticals, Inc. (TARS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Illumina (ILMN) Partners With Henry Ford Health for NGS Test
by Zacks Equity Research
Illumina (ILMN) collaborates with Henry Ford Health to conduct a series of studies that is likely to focus on the genetic drivers of cardiovascular disease.
Illumina (ILMN) to Expand Genomics Capacity With New Pact
by Zacks Equity Research
Illumina's (ILMN) recent collaboration is built on the shared goal of the organizations to expand sequencing capabilities and capacity for all people in Africa.
Illumina's (ILMN) NovaSeq X Exceeds 200 Order Milestone
by Zacks Equity Research
Illumina's (ILMN) NovaSeq X records the strongest pre-launch demand ever witnessed for any instrument.
Illumina (ILMN) to Enable Tertiary Analysis With New Launch
by Zacks Equity Research
Illumina's (ILMN) Connected Software is an end-to-end software system that standardizes analysis tools and connects data across the genomics workflow.
Why Is Seattle Genetics (SGEN) Up 24.6% Since Last Earnings Report?
by Zacks Equity Research
Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Illumina (ILMN) Unveils Complete Long Reads Technology
by Zacks Equity Research
Illumina's (ILMN) Complete Long Read Prep combines Illumina sequencing by synthesis chemistry with DRAGEN secondary analysis to provide WGS with more accuracy.
Company News for Mar 14, 2023
by Zacks Equity Research
Companies In The News Are: SGEN, PFE, PODD, SIVB, ILMN, PNC.
Steer Clear Of These 4 Toxic Stocks to Avoid Losses
by Rimmi Singhi
Correctly spotting overpriced stocks and shunning them at the right time may avoid portfolio bleeding. ILMN, LTRX, BSY and CDMO are a few such toxic stocks.
Myriad Genetics' (MYGN) New Pact to Extend HRD Testing Access
by Zacks Equity Research
Myriad Genetics (MYGN), together with Illumina, will seek joint HRD companion diagnostics partnerships with pharmaceutical companies globally.
Illumina (ILMN) Q4 Earnings Miss Estimates, Gross Margin Down
by Zacks Equity Research
Delays in recruitment for some large research projects in the Americas and Europe, the impact of COVID disruptions in China and foreign exchange woes hurt Illumina's (ILMN) Q4 revenues.
Illumina (ILMN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Illumina (ILMN) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Illumina (ILMN) Misses Q4 Earnings Estimates
by Zacks Equity Research
Illumina (ILMN) delivered earnings and revenue surprises of -26.32% and 1.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Illumina (ILMN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in the Cards for Illumina (ILMN) in Q4 Earnings?
by Zacks Equity Research
Negative foreign exchange impact and consumables inventory deleveraging are expected to have affected Illumina's (ILMN) top line during the fourth quarter.
These 4 Toxic Stocks May Bring Bad Luck to Your Portfolio
by Rimmi Singhi
Consider dumping toxic stocks like BALY, OMCL, ILMN and AY from your portfolio to avoid huge losses.
Illumina (ILMN), Nashville Biosciences Partner With Amgen
by Zacks Equity Research
Illumina (ILMN) is currently keeping well with its goals to strengthen its foothold in the multi-billion gene sequencing market globally.